علاج سرطان الدم الحاد النخاعي المشخص حديثاً لدى كبار السن (العمر ≥55) المرشحين للعلاج المكثف

References

1. For older adults with newly diagnosed AML considered candidates for intensive ALT, the ASH guideline panel suggests conventional induction and postremission therapy over HMA or LDAC monotherapy induction and postremission therapy (conditional recommendation based on low certainty in the evidence of effects ⨁⨁◯◯).
2. Conventional induction and postremission therapy may be preferred for patients who have favorable-risk cytogenetics or molecular mutations and for those for whom a long hospital stay would not be a deterrent.
3. For older adults with newly diagnosed AML considered candidates for intensive ALT, the ASH guideline panel suggests using either conventional induction and postremission therapy or HMA- or LDAC-based induction and postremission therapy in combination with venetoclax (conditional recommendation based on very low certainty in the evidence of effects ⨁◯◯◯).
4. For older adults with AML who achieve remission after at least a single cycle of conventional induction therapy and who are not candidates for allogeneic hematopoietic stem cell transplantation (allo-HCT), the ASH guideline panel recommends postremission therapy over no additional therapy (strong recommendation based on low certainty in the evidence of effects ⨁⨁◯◯).
5. Conventional therapy increases CR rates (odds ratio, 1.75; 95% CI, 1.25-2.38; high certainty in evidence).
6. Postremission therapy probably decreases relapse at the longest follow-up (RR, 0.83; 95% CI, 0.70-0.98; mean, 51 months follow-up; moderate certainty in evidence).